CBAY

0.00

100.00% -32.48

Dopo l'orario di chiusura: 32.48 32.48 +

Cymabay Therapeutics Inc (CBAY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$32.48

Aprire:

Volume 24 ore:

Capitalizzazione di mercato:

$3.73B

Reddito:

Utile/perdita netta:

$-105.37M

Rapporto P/E:

0.00

EPS:

-0.88

Flusso di cassa netto:

$-72.98M

1 W Prestazione:

-100.00%

1M Prestazione:

-100.00%

6M Prestazione:

-100.00%

1 anno Prestazione:

-100.00%

Intervallo 1D:

$0.00

Portata 52W:

$0.00

$32.50

Cymabay Therapeutics Inc Stock (CBAY) Company Profile

Nome

Cymabay Therapeutics Inc

Settore

Healthcare (1209)

Industria

Biotechnology (699)

Telefono

510-293-8800

Indirizzo

7999 Gateway Boulevard, Suite 130, Newark, CA

Dipendente

Cinguettio

@CymaBay

Prossima data di guadagno

2024-03-14

Ultimi documenti SEC

CBAY's Discussions on Twitter

Cymabay Therapeutics Inc Stock (CBAY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-13	Downgrade	Raymond James	Outperform → Mkt Perform
2023-08-14	Iniziato	UBS	Buy
2023-08-11	Iniziato	Guggenheim	Buy
2023-04-05	Iniziato	William Blair	Outperform
2023-03-09	Iniziato	BTIG Research	Buy
2022-04-11	Ripresa	Cantor Fitzgerald	Overweight
2020-08-04	Reiterato	H.C. Wainwright	Buy
2020-07-31	Iniziato	Piper Sandler	Overweight
2020-05-26	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-05-12	Aggiornamento	Evercore ISI	In-line → Outperform
2020-05-12	Aggiornamento	ROTH Capital	Neutral → Buy
2020-05-12	Aggiornamento	Raymond James	Mkt Perform → Outperform
2020-05-12	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2020-05-12	Aggiornamento	Stifel	Hold → Buy
2020-03-13	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-03-13	Aggiornamento	Oppenheimer	Perform → Outperform
2019-11-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2019-11-26	Downgrade	H.C. Wainwright	Buy → Neutral
2019-11-26	Downgrade	ROTH Capital	Buy → Neutral
2019-11-26	Downgrade	Raymond James	Strong Buy → Mkt Perform
2019-11-25	Downgrade	Evercore ISI	Outperform → In-line
2019-11-25	Downgrade	Stifel	Buy → Hold
2019-11-25	Downgrade	SunTrust	Buy → Hold
2019-06-25	Iniziato	Stifel	Buy
2019-06-12	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-05-14	Iniziato	Citigroup	Buy

Mostra tutto

Cymabay Therapeutics Inc Borsa (CBAY) Ultime notizie

BTIG Maintains Cymabay Therapeutics (CBAY) Buy Recommendation - MSN

MSN

CymaBay (CBAY) Stock Up on Positive Results From PBC Study - Yahoo Movies Canada

Yahoo Movies Canada

CymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Canada Shine On

Yahoo Canada Shine On

CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated by Analysts at StockNews.com - Defense World

Defense World

CymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated at StockNews.com - Defense World

Defense World

Gilead posts quarterly loss, revenue rises 5% - WTVB

WTVB

Cymabay Therapeutics Inc Azioni (CBAY) Dati Finanziari

Cymabay Therapeutics Inc (CBAY) Reddito netto 2024

CBAY l'utile netto (TTM) è stato di -$105.37 milioni per il trimestre terminato il 2023-12-31, un +0.60% aumento anno su anno.

Cymabay Therapeutics Inc (CBAY) Flusso di cassa 2024

CBAY ha registrato un flusso di cassa disponibile (TTM) di -$72.98 milioni per il trimestre conclusosi con 2023-12-31, un +13.36% aumento anno su anno.